CCR5Δ32 Polymorphism and Inflammatory Bowel Disease: A Case-Control and Genotype-Phenotype Study in a Polish Population.

Pawel Petryszyn, Klaudia Koj, Robert Dudkowiak, Agnieszka Gruca, Elzbieta Poniewierka, Krystyna Głowacka

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pawel PetryszynDepartment of Clinical Pharmacology, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.ORCID 0000-0003-2397-7028

Klaudia KojDepartment of Clinical Pharmacology, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.

Robert DudkowiakDepartment of Gastroenterology and Internal Medicine, University Clinical Center, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland.

Agnieszka GrucaDepartment of Clinical Pharmacology, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.

Elzbieta PoniewierkaDepartment of Gastroenterology, Hepatology and Internal Medicine, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland.

Krystyna GłowackaDepartment of Clinical Pharmacology, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C-C chemokine receptor 5 (CCR5) contributes to leukocyte trafficking and intestinal inflammation, whereas the functional CCR5Δ32 deletion markedly impairs receptor expression. Its role in inflammatory bowel disease (IBD) susceptibility remains uncertain. We evaluated CCR5Δ32 in 274 patients with IBD, including 141 with Crohn's disease (CD) and 133 with ulcerative colitis (UC), and 100 controls using polymerase chain reaction genotyping; phenotype-related associations were explored in a clinically characterized subgroup. Overall CCR5 genotype distributions did not differ between patients with IBD and controls (

Indexed as

Colitis, UlcerativeCrohn DiseaseGenetic Predisposition to DiseaseInflammatory Bowel DiseasesPolymorphism, GeneticReceptors, CCR5AdultAllelesCase-Control StudiesFemaleGene FrequencyGenetic Association StudiesGenotypeHumansMaleMiddle AgedCCR5 protein, humanReceptors, CCR5CCR5CCR5Δ32chemokine receptorCrohn’s diseasegenetic polymorphisminflammatory bowel diseaseleukocyte traffickingsex differencesulcerative colitis

Identifiers

PMID42794723

DOI10.3390/ijms27188297

PMCPMC13607550

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.